Crossmark

The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro

Crossref DOI link: https://doi.org/10.1186/s41927-018-0040-9

Published Online: 2018-11-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Stougaard, Julie

Lomholt, Søren

Ommen, Pernille

Kelsen, Jens

Kragstrup, Tue W. http://orcid.org/0000-0002-6439-397X
Funding

Funding for this research was provided by:

Gigtforeningen

Aage Bangs Foundation

Nyegaard Foundation

Augustinus Fonden

Bjarne Jensen Foundation

Sundhedsvidenskabelige Fakultet, Aarhus Universitet
License Information

Text and Data Mining valid from 2018-11-19
More Information

Article History

Received: 22 May 2018

Accepted: 14 October 2018

First Online: 19 November 2018

Ethics approval and consent to participate

: Samples were collected at the outpatient clinic at Aarhus University Hospital. All samples were obtained after informed written consent according to the Declaration of Helsinki and approved by the Local Ethics Committee (project number 20121329) and the Danish Data Protection Agency.

: Not applicable.

: TWK is an Editorial Board Member for BMC Rheumatology. The authors’ declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.